Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Buse, John B; Rosenstock, Julio; Sesti, Giorgio; Schmidt, Wolfgang E; Montanya, Eduard; Brett, Jason H; Zychma, Marcin; Blonde, LawrenceLancet; 2009 Jul 4;374(9683):39-47. PMID: 19515413Category: GLP-1sTags: GLP-1 agonists
Incretin-based therapies for type 2 diabetes mellitus. Lovshin, Julie A; Drucker, Daniel JNature reviews. Endocrinology; 2009 May;5(5):262-9. PMID: 19444259Category: GLP-1s
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Bunck, Mathijs C; Diamant, Michaela; Cornér, Anja; Eliasson, Bjorn; Malloy, Jaret L; Shaginian, Rimma M; Deng, Wei; Kendall, David M; Taskinen, Marja-Riitta; Smith, Ulf; Yki-Järvinen, Hannele; Heine, Robert JDiabetes care; 2009 May;32(5):762-8. PMID: 19196887Category: GLP-1sTags: metforminglycemic controlGLP-1 agonists
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Garber, Alan; Henry, Robert; Ratner, Robert; Garcia-Hernandez, Pedro A; Rodriguez-Pattzi, Hiromi; Olvera-Alvarez, Israel; Hale, Paula M; Zdravkovic, Milan; Bode, Bruce; , Lancet; 2009 Feb 7;373(9662):473-81. PMID: 18819705Category: GLP-1sTags: sulfonylureas (SUs)glycemic controlGLP-1 agonists
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Drucker, Daniel J; Buse, John B; Taylor, Kristin; Kendall, David M; Trautmann, Michael; Zhuang, Dongliang; Porter, LisaLancet; 2008 Oct 4;372(9645):1240-50. PMID: 18782641Category: GLP-1s
GLP-1: physiological effects and potential therapeutic applications. Aaboe, Kasper; Krarup, Thure; Madsbad, Sten; Holst, Jens JuulDiabetes, obesity & metabolism; 2008 Nov;10(11):994-1003. PMID: 18435775Category: GLP-1s
Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice. Suarez-Pinzon, Wilma L; Lakey, Jonathan R T; Rabinovitch, AlexCell transplantation; 2008;17(6):631-40. PMID: 18819251Category: GLP-1sTags: beta cell pathophysiologyDPP-4 inhibitors
Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Salehi, Marzieh; Aulinger, Benedikt A; D'Alessio, David AEndocrine reviews; 2008 May;29(3):367-79. PMID: 18292465Category: GLP-1s
Exenatide and rare adverse events. Ahmad, Syed R; Swann, JoslynThe New England journal of medicine; 2008 May 1;358(18):1970-1; discussion 1971-2. PMID: 18456920Category: GLP-1s
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Amori, Renee E; Lau, Joseph; Pittas, Anastassios GJAMA : the journal of the American Medical Association; 2007 Jul 11;298(2):194-206. PMID: 17622601Category: GLP-1s